4th Asia-Pacifi c Abstracts A525 ling. METHODS: A cross-sectional study design using convenience sampling technique was used in this study. A validated self-administered questionnaire using 5 point Likert scale was distributed to 440 respondents in the State of Penang, Malaysia. The Statistical Package of Social Science (SPSS Inc., Chicago, IL) for Windows version 12.0 was used for all the statistical tests and a p-value of <0.05 was considered statistically signifi cant. RESULTS: The result revealed that majority of the respondents (69.3%), understand the roles of community pharmacists in patients' education and counselling. More than half of them (66.3%) are aware of the availability of medical counselling provided by community pharmacists. Majority of the respondents (66.8%), are aware that community pharmacists are well-trained to provide medical education and counselling. On the other hand, less than half of the respondents (46.6%) perceive that pharmacists are the best people to provide medical education and counselling to the public. About 70% of the respondents had mentioned that the pharmacist will ask them about their medical conditions and allergies before recommending any medications. Respondents also found that: pharmacists are very approachable for giving medical education and counselling (56.4%); community pharmacists help them to explain the misconceptions that they had in health care (59.0%); they have changed for healthier lifestyles after being exposed to medical education and counselling by community pharmacists (58.2%). CONCLUSIONS: The present study also found that the respondents are generally well aware and satisfi ed toward the medical education and counselling provided by community pharmacists in the state of Penang, Malaysia.
1
Griffi th University, Brisbane, Queensland, Australia; 2 Griffi th University, Meadowbrook, Queensland, Australia; 3 University of Queensland, Brisbane, Queensland, Australia OBJECTIVES: To determine the effect of including the costs and risks of medical negligence claims on the results of a cost-utility model of diagnostic strategies for patients with chest pain presenting at the Emergency Room. Coronary computed tomography (CT) has been proposed as an initial screening technique for patients at low risk of coronary artery disease, because it may allow earlier discharge and cost savings compared with stress-based tests such as exercise single-photon emitting computed tomography (SPECT) or exercise echocardiography (E x E). METHODS: A decision-analytic model was designed to calculate the expected costs and health outcomes at 12 months for patients at low risk of coronary artery disease presenting at the Emergency Room with chest pain. Published data was used to predict the accuracies of the diagnostic tests. Costs were calculated from the perspective of the Australian health system, and a rate (30%) and cost of litigation ($160,000) was included for false negative diagnoses that incurred an event within the time frame. RESULTS: ExE was the least costly strategy in the base case analysis. The results are sensitive to changes in the cost and likelihood of litigation, because these costs are high relative to the other costs in the model. At a 30% claim rate, if the expected payout for litigation is <$150,000, CT is the most cost-effective option, with lower costs and higher QALYs. The ICERs are high because the differences in QALYs are small. In contrast, at the expected cost of litigation in the United States ($1,000,000), the strategy with lowest event rate (SPECT) is the least costly strategy. CONCLU-SIONS: Litigation costs for medical negligence can change the outcomes of cost-utility analyses. We consider that these should be assessed and included when an analysis is undertaken from the societal perspective.
PCV46 A SURVEY EXPLORING KNOWLEDGE AND PERCEPTIONS OF GENERAL PRACTITIONERS TOWARD THE USE OF GENERIC MEDICINES IN THE NORTHERN STATE OF MALAYSIA
Hassali MA, Shafi e AA Universiti Sains Malaysia, Minden, Penang, Malaysia OBJECTIVES: To evaluate knowledge and perceptions of Malaysian general medical practitioners (GPs) on issues surrounding the safety, effi cacy, and quality of generic medicines. METHODS: A postal cross-sectional survey involving registered GPs (n = 325) in Penang, Malaysia was undertaken. The questionnaire consisted 23-item and validated accordingly before it been sent to the GPs. At the end of the survey period, a total of 87 GPs responded to the survey (Response rate of 26.8%). RESULTS: The majority of the respondents (85.1%) claimed that they actively prescribed generic medicines in their practice. On the other hand, only 4.6% of the respondents correctly identifi ed the Malaysia's National Pharmaceutical Control Bureau's bioequivalence standard for generic products. There were misconceptions among the respondents about the concepts of "bioequivalence," "effi cacy," "safety," and "manufacturing standards" of generic medicines. GPs in this survey believed that a standard guideline on brand substitution process, collaboration with pharmacists, patient education and information on safety and effi cacy of generic medicines were necessary to ensure quality use of generics. Furthermore, advertisements and product bonuses offered by pharmaceutical companies, patient's socio-economic factors as well as credibility of manufacturers were factors reported to infl uence their choice of medicine. CONCLU-SIONS: As a conclusion, although it appeared that GPs have largely accepted the use of generic medicines, they still have concerns regarding the reliability and quality of such products. GPs need to be educated and reassured about generic products approval system in Malaysia concerning bioequivalence, quality, and safety.
PCV47 ASSOCIATION BETWEEN HOSPITAL PROCESS PERFORMANCE AND OUTCOME OF PATIENTS WITH ACUTE MYOCARIDAL INFARCTION
Tan CH 1 , Tam SC 2 , Yang MC 1 1 National Taiwan University, Taipei, Taiwan; 2 Chang Jung Christian University, Tainan County, Taiwan OBJECTIVES: Much literature has proved that process of care in acute myocardial infarction (AMI) patients has signifi cant effect on mortality and prognosis. However, little study has discussed about the association between hospital process performance and patients' outcome. The objective of this study was to investigate the association between hospitals care process and patients' outcome while controlling for potential confounders, including coexisting conditions, severity of illness and process performance of hospitals in Taiwan. METHODS: The claimed data came from the National Health Insurance Research Database for inpatient treatment for AMI in 2007 to 2008. Totally 109 hospitals and 899 patients were enrolled in this study. Main outcome measures were 6 ACC/AHA class I guideline-recommended treatments and the correlation between hospitals' individual care processes performance and 30-day mortality rate of patients. We tested the association between the process and outcome for each hospital by using a hierarchical linear model (HLM) for each process measure. RESULTS: Over all, the average eligible rate among six ACC/AHA guideline-recommended treatments was 42.38%. The eligible rate of reperfusion was signifi cantly different between public, nonprofi t and private hospitals (P = 0.0004). Factors highly correlated with 30-day mortality rate of patients included using aspirin (OR = 0.97, P < 0.0001), using lipid-lowering agents (OR = 0.99, P = 0.005) and having reperfusion (OR = 0.99, P = 0.05) at admission. CONCLUSIONS: Signifi cant associations between hospital care process and patients' outcomes were found. The results supported the use of guideline-based performance measures which can help improving hospital quality.
PCV48

ST. VINCENT'S PRIVATE HOSPITAL VENOUS THROMBOEMBOLISM PREVENTION PROJECT: ANALYSIS OF REDUCED COST AND IMPROVED CLINICAL OUTCOMES
Duff J 1 , Walker K 1 , Lee J 2 , Stratton C 2 1 St Vincent's Private Hospital, Sydney, NSW, Australia; 2 Sanofi -Aventis Australia, Sydney, NSW, Australia OBJECTIVES: Prophylaxis with a low molecular weight heparin (LMWH) such as enoxaparin or a low-dose unfractionated heparin (LDUH) in high risk medical and surgical patients is consistent with the recommendations made by the American College of Chest Physicians Eighth Conference on Antithrombotic and Thrombolytic Therapy. While these guidelines present strong evidence to support the use of prophylaxis to prevent venous thromboembolism (VTE), they are not always adhered to in clinical practice. The St. Vincent's Private Hospital VTE Prevention Project aimed to improve compliance with best practice prophylaxis in hospitalized patients. An audit of the rates of prophylaxis was conducted over a 12-month period as part of this project. The aim of this analysis was to determine whether the measures implemented as a result of the St. Vincent's project translated into cost savings and improved clinical outcomes. METHODS: A decision-analytic model was constructed using audit data from 21,942 medical and surgical patients admitted to St. Vincent's who received either enoxaparin 40 mg daily, unfractionated heparin (UFH) three times daily (TID) or no prophylaxis. The rate of prophylaxis at baseline was compared with that at the end of the audit for each prophylaxis regimen. Clinical trial data was used to estimate the incidence of VTE (defi ned as deep vein thrombosis [DVT] and pulmonary embolism [PE]), and major bleeding. RESULTS: As a result of the measures introduced to improve adherence to best practice, we estimated 13 fewer deaths, 84 fewer symptomatic DVTs, 19 fewer symptomatic PEs and 512 fewer hospital bed days over baseline, across all medical and surgical patients. We also estimated that overall costs were reduced by $245,439 over 12 months. CONCLUSIONS: Improved adherence to best practice in VTE prophylaxis in the Australian clinical setting is likely to result in fewer deaths, VTE events and signifi cant overall cost savings.
PCV49 THE EVALUATION OF CARE PATHWAYS AS A COMPLEX INTERVENTION: APPLICATION OF A METHODOLOGICAL FRAMEWORK
Panella M Amedeo Avogadro University, Novara, Italy OBJECTIVES: To assess the extent to which the development steps of the evaluation of care pathways (CP) can be represented in the framework for the design and evaluation of complex interventions. METHODS: The framework is composed by fi ve phases: theoretical (pre-clinical), identifi cation of components of the intervention (phase I), defi nition of trial and intervention design (phase II), main trial execution (phase III), promoting effective implementation (phase IV). RESULTS: The framework was applied to the evaluation of CP for strokes. Pre-clinical phase was aimed in synthesizing the evidences: three reviews were selected and showed that CP are theoretically applicable in stroke care and that mortality should be the main outcome to be analyzed. Phase I was done through a descriptive pilot. A total of 253 consecutive patients admitted for strokes in 29 hospitals were analyzed. Overall in-hospital stroke mortality was 19.76%. Stroke teams (OR = 0.25; P = 0.025), antithrombotic therapy (OR = 0.26; P = 0.009) and complications (OR = 6.40; P < 0.001) were independent predictors of in-hospital mortality. Therefore these variables were selected as components of CP or treated as covariates. Because CP are active both on organizational (units) and individual (patients) level, a two-arm cluster Randomized Controlled Trial with hospitals and long-term rehabilitation facilities as randomization units was designed in phase II. Fourteen units were randomized either to arm 1 (CP) or to arm 2 (usual care) including 238 patients per group. The primary outcome measure was mortality, the CP were also analyzed with key quality indicators. The trial has been successfully performed (phase III) and in-hospital mortality has been reduced (OR = 0.10; P = 0.04). Because the adjusted results are not available yet, it was not possible to identify the active components of the CP and therefore phase IV has not been performed. CONCLUSIONS: Even if the results are still partial, it seems possible to apply this framework to the study of CP.
DIABETES/ENDOCRINE DISORDERS -Clinical Outcomes Studies
PDB1 CLINICAL OUTCOMES WITH DPP4 INHIBITORS IN SINGAPORE
Narayanaswamy S, Goh LF, Yip WL Singapore General Hospital, Singapore OBJECTIVES: 1) Compare effi cacy and safety of sitagliptin and vildagliptin in type 2 diabetes; and 2) Examine prescription of concomitant oral hypoglycemic agents (OHAs) and insulin. METHODS: We conducted a retrospective database study, drawing information from all patients treated at Singapore Health Services cluster institutions over 1.5-year study period. Inclusion criteria: HbA1C >7%, naive to gliptins, and remained on gliptin for at least 90 days (from pharmacy records). Exclusion criteria: patients who switched gliptins, and HbA1c not tested within 10 days of exit timepoint. IRB approval was obtained. RESULTS: Sitagliptin (n = 340) and vildagliptin (n = 92) patients met inclusion and exclusion criteria. General demographics matched at baseline (all P > 0.05). Mean duration of gliptin treatment 242 days (sitagliptin) versus 220 days (vildagliptin) (P = 0.944). Mean baseline HbA1c matched at 8.95% (sitagliptin) versus 9.18% (vildagliptin) (P = 0.15). At exit, sitagliptin arm demonstrated absolute HbA1c reduction of −0.643% versus vildagliptin −0.728% (P = 0.61); percentage reduction in HbA1c was sitagliptin −6.55% versus vildagliptin −7.589% (p = 0.44). Subgroup analyses of a) patients with entry HbA1c >8%; b) stratifi cation of outcome by dose of gliptin; and c) addition or discontinuation of OHA from baseline all did not demonstrate statistically signifi cant difference. Majority of patients were not on maximal OHA doses at gliptin initiation, however total daily doses of OHAs was not signifi cantly different at exit versus baseline for both arms. Almost 90% of patients in both groups received multiple OHAs for diabetes control. Change in creatinine clearance was comparable in both arms. Safety endpoints microalbuminuria/creatinine ratio, average % weight change and incidence of pancreatitis were not signifi cantly different between both arms (all P > 0.05). Five sitagliptin patients required hospital admission for severe hypoglycemia vs 0 vildagliptin patients. CONCLUSIONS: We present our initial fi ndings that vildagliptin is non-inferior to sitagliptin in HbA1c-lowering effi cacy. Both products are well-tolerated without signifi cant differences in safety endpoints save severe hypoglycemia in sitagliptin arm.
PDB2
LONG-TERM HEALTH OUTCOMES OF TREATMENT WITH LIRAGLUTIDE VERSUS GLIMEPRIRIDE IN TYPE 2 DIABETES PATIENTS IN ASIAN SETTING
Wu J 1 , Wu JH 2 , Chang J 3 1 Tianjin University, Tianjin, China; 2 306 Hospital of PLA, Beijing, China; 3 Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China OBJECTIVES: To evaluate the long-term health outcomes associated with Liraglutide 1.2 and 1.8 mg versus Glimepiride 4 mg all combined with Metformin in Asian patients with type 2 diabetes (T2D). METHODS: A published and validated computer simulation model of diabetes (CORE Diabetes Model) was used to make the projection of long-term health outcomes (30 years). Simulated cohorts and treatment effects were derived from 928 T2D patients in the NCT00614120 trial held in China, South Korea and India. HbA1C was signifi cantly reduced in Liraglutide 1.2 mg, Liraglutide 1.8 mg, and Glimepiride groups (−1.3%, −1.4%, and −1.3% respectively). Liraglutide treatments led to greater reduction in Body Mass Index and systolic blood pressure versus Glimepride. No major hypoglycemia was reported in Liraglutide groups, while the rate of major hypoglycemia for Glimepride was 0.029 per patient-year. The rate of minor hypoglycemia was lower in Liraglutide groups than Glimepiride. An annual discounting rate of 3% was used for health and cost outcomes. One-way sensitivity analysis was performed. RESULTS: The treatments of Liraglutide compared with Glimepiride were projected to reduce the cumulative incidences of diabetes complications and improve long term health outcomes for patients with T2D. For Liraglutide 1.2 mg, the cumulative incidences of background retinopathy, end stage renal disease, ulcer, and congestive heart failure event were reduced 0.20%, 0.086%, 0.020% and 0.53% respectively, discounted life expectancy was increased 0.058 year and quality adjusted life-years (QALY) was increased 0.11 QALY. For Liraglutide 1.8mg, the incidences reduction were 0.61%, 0.12%, 0.34% and 0.63% respectively, discounted life expectancy was improved 0.051 year, and 0.107 QALY. CONCLUSIONS: Liraglutide 1.2 mg and 1.8 mg therapy could delay the onset of diabetes complications and reduced related cumulative incidences over patient lifetimes compared with Glimepiride. It improved the life expectancy and quality adjusted life expectancy in Asian patients with T2D.
PDB3
EFFECTS OF EXTENDED-RELEASE VERSUS IMMEDIATE-RELEASE GLIPIZIDES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Wang L 1 , Sun X 2 , Li Y 3 1 Sichuan University, Chengdu, Sichuan, China; 2 McMaster University, Hamilton, ON, Canada; 3 West China Hospital, Sichuan University, Chengdu, China OBJECTIVES: To address effects of extended-release versus immediate-release glipizide on glucose control, insulin secretion, and compliance. METHODS: We included parallel randomized trials and cohort studies (only for compliance assessment) comparing extended-release versus immediate-release glipizide for type 2 diabetes. We searched Medline, EMBASE, the Cochrane Library, and Chinese Biomedical database, screened reference lists, and contacted pharmaceutical company. We pooled data using random-effect model and explored heterogeneity by pre-specifi ed hypotheses. RESULTS: Sixteen trials involving 1062 patients and two retrospective cohort studies of 13,452 patients were included. Trials are of inadequate quality. No trials reported patient-important outcomes. The reduction of fasting plasma glucose from the baseline appeared larger in extended-release than immediate-release glipizide (mean difference −0.30 mmol/L, 95% CI −0.57 to −0.03). The reduction was not signifi cant different between two drugs in HbA1c (−0.03%, −0.20% to 0.15%) and 2-hour postprandial plasma glucose (−0.28 mmol/L, −1.12 to 0.55). Extended-release glipizide appeared to reduce insulin secretion from the baseline, whereas immediate-release formulation increased the secretion (fasting insulin: −0.86 vs. 0.28 μIU/ml; 2-hour postprandial insulin: −2.94 vs. 0.24 μIU/ml). Patients administering extended-release glipizide had less hypoglycemia (Peto odds ratio 0.26, 95% CI 0.08 to 0.81) and lower missed dosing (Peto odds ratio 10.24, 95%CI 5.22 to 20.08). The cohort studies showed results in compliance consistent with trials. CONCLUSIONS: The two drugs may have comparable effects on glucose control. Extended-release glipizide might achieve glucose control with decreased insulin secretion, and fewer hypoglycemic episodes. The fi ndings are inconclusive due to inadequate study quality, short follow-up, and unavailability of patient important outcomes.
DIABETES/ENDOCRINE DISORDERS -Cost Studies
PDB4 MEDICAL SERVICE COST ASSOCIATED WITH PIOGLITAZONE AND SULFONYLUREA TREATMENT AMONG TYPE 2 DIABETIC PATIENTS ENROLLED IN A US INTEGRATED HEALTH-CARE SYSTEM
Sun SX 1 , Ma L 2 , Bron M 1 , Lamothe K 2 , Boulanger L 3 Takeda Pharmaceuticals International, Deerfi eld, IL, USA; 2 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA; 3 United BioSource Corporation, Lexington, MA, USA OBJECTIVES: To assess overall and diabetes-related medical service costs associated with pioglitazone (PIO) and sulfonylureas (SU) treatment among T2DM patients. METHODS: This is a retrospective cohort study based on electronic medical records (January 1, 2004-January 31, 2009) from the Geisinger Clinic in the Northeastern region of the United States. The date of the initial prescription for PIO or SU was denoted as the index date. Patients were required to be aged 18 years or older and prescribed an oral antidiabetic treatment in the 1 year prior to index. Patients with type 1 or gestational diabetes and prior insulin use were excluded, as were those who had prescriptions for the index drug in the 90 days prior. Propensity score 1:1 matching and a second stage of generalized linear regression were employed to assess overall and diabetes-related medical service costs (pharmacy costs were not available in the database) in the 2 years following the index date, adjusting for patient demographics, baseline comorbidities, medication use, and health-care resource utilization. RESULTS: A total of 2758 patients, 1379 each in the PIO and SU cohorts, were analyzed. For both cohorts, mean age was 62 years, 46% were male, and 96% were Caucasian. The two cohorts were similar in terms of current smoking status and diabetes-related comorbidities. The unadjusted total and diabetes-related medical costs were $1258 and $705 higher for SU versus PIO patients. After adjusting for covariates, the overall and diabetes-related medical service costs remained higher for patients receiving SU versus PIO ($8360 vs. $7400 for overall, and $5577 vs. $5238 for diabetes-related costs, P < 0.05 for both comparisons). CONCLUSIONS: Over a 2-year follow-up, patients with T2DM initiated on PIO therapy in an integrated system incurred lower overall and diabetes-related medical service costs than patients initiated on SU. Further studies describing clinical and humanistic aspects of PIO versus SU are warranted.
PDB5 TOTAL AND DIABETES-RELATED COSTS ASSOCIATED WITH HYPOGLYCEMIA IN TYPE 2 DIABETES MELLITUS PATIENTS INITIATED ON ORAL ANTIDIABETIC DRUGS FROM A LARGE US MANAGED CARE COHORT
Bron M 1 , Yu A 2 , Marynchenko M 3 , Sun SX 1 , Yang H 2 , Wu EQ 2 1 Takeda Pharmaceuticals International, Deerfi eld, IL, USA; 2 Analysis Group, Inc., Boston, MA, USA; 3 Analysis Group, Inc., Montreal, QC, Canada OBJECTIVES: To estimate annual health-care costs associated with hypoglycemia among T2DM patients initiated on oral antidiabetic drugs (OADs) in a large managed care cohort with managed care insurance benefi ts. METHODS: T2DM patients initiated on OADs were selected from the Ingenix Impact database (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) . Patients aged 18 years or older with at least 1 year of continuous eligibility following the index date (the fi rst OAD prescription fi ll date) who were diagnosed with moderate to severe
